Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tucidinostat - HUYA Bioscience International

Drug Profile

Tucidinostat - HUYA Bioscience International

Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000; Hiyasta

Latest Information Update: 08 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Developer Chipscreen Biosciences; GNT Biotech and Medicals Corporation; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; Zhejiang University
  • Class Acrylamides; Aminopyridines; Antineoplastics; Antivirals; Benzamides; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; HDAC1 protein inhibitors; HDAC10 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Peripheral T-cell lymphoma
  • Registered Adult T-cell leukaemia-lymphoma
  • Phase III Brain metastases; Diffuse large B cell lymphoma; Malignant melanoma
  • Phase II/III Cutaneous T-cell lymphoma; HIV infections
  • Phase II Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 05 Oct 2021 Biomarkers information updated
  • 05 Oct 2021 Chipscreen Biosciences plans a phase II trial for Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) in November 2021 (NCT05068427)
  • 23 Jun 2021 Registered for Adult T-cell leukaemia-lymphoma (Monotherapy, Second-line therapy or greater, In adults) in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top